Infectivity assessment of porcine endogenous retrovirus using high-throughput sequencing technologies.


Journal

Biologicals : journal of the International Association of Biological Standardization
ISSN: 1095-8320
Titre abrégé: Biologicals
Pays: England
ID NLM: 9004494

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 02 02 2021
revised: 06 05 2021
accepted: 10 05 2021
pubmed: 28 5 2021
medline: 24 11 2021
entrez: 27 5 2021
Statut: ppublish

Résumé

Xenogenic cell-based therapeutic products are expected to alleviate the chronic shortage of human donor organs. For example, porcine islet cell products are currently under development for the treatment of human diabetes. As porcine cells possess endogenous retrovirus (PERV), which can replicate in human cells in vitro, the potential transmission of PERV has raised concerns in the case of products that use living pig cells as raw materials. Although several PERV sequences exist in the porcine genome, not all have the ability to infect human cells. Therefore, polymerase chain reaction analysis, which amplifies a portion of the target gene, may not accurately assess the infection risk. Here, we determined porcine genome sequences and evaluated the infectivity of PERVs using high-throughput sequencing technologies. RNA sequencing was performed on both PERV-infected human cells and porcine cells, and reads mapped to PERV sequences were examined. The normalized number of the reads mapped to PERV regions was able to predict the infectivity of PERVs, indicating that it would be useful for evaluation of the PERV infection risk prior to transplantation of porcine products.

Identifiants

pubmed: 34039532
pii: S1045-1056(21)00040-3
doi: 10.1016/j.biologicals.2021.05.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ken Kono (K)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.

Kiyoko Kataoka (K)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.

Yuzhe Yuan (Y)

Graduate School of Science, Technology and Innovation, Kobe University, Hyogo, Japan.

Keisuke Yusa (K)

Graduate School of Science, Technology and Innovation, Kobe University, Hyogo, Japan.

Kazuhisa Uchida (K)

Graduate School of Science, Technology and Innovation, Kobe University, Hyogo, Japan.

Yoji Sato (Y)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan; LiSE Laboratory, Kanagawa Institute of Industrial Science and Technology, Kanagawa, Japan; Department of Translational Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; Department of Cellular and Gene Therapy Products, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan. Electronic address: yoji@nihs.go.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH